Cell Therapy: Forge Biologics Labcorps collobration aims to accelerate gene therapy
Forge Biologics and Labcorp have entered into a collaboration to accelerate gene therapy development and commercialization. Forge Biologics is a gene therapy-focused contract development and manufacturing organization, while Labcorp is a leading global life sciences company that provides diagnostic and drug development services.
The collaboration aims
to leverage Forge Biologics' expertise in adeno-associated virus (AAV) gene
therapy development and Labcorp's capabilities in clinical
trial management, biomarker analysis, and diagnostic testing to accelerate
the development of gene therapies. As part of the collaboration, Labcorp will
provide clinical trial testing and biomarker analysis services, while Forge
Biologics will provide AAV gene therapy development and manufacturing services.
The collaboration will
initially focus on advancing Forge Biologics' gene therapy pipeline, including
its lead product candidate, FBX-101, for the treatment of Krabbe
disease. The companies plan to expand the collaboration to include other
gene therapy programs in the future.
Overall, this
collaboration has the potential to accelerate the development and
commercialization of gene therapies, which could have a significant impact on
the treatment of genetic
diseases.
Comments
Post a Comment